In the ever-evolving landscape of the biopharma industry, staying informed is crucial. The latest updates highlight significant moves from companies like Capricor Therapeutics and Bristol Myers Squibb, alongside developments at Eli Lilly, Kynexis, and the newly formed Network Bio.
Capricor’s Governance Challenges
Capricor Therapeutics finds itself under the scrutiny of activist investor Kaos Capital, which is advocating for a “governance reset” ahead of an essential FDA decision regarding the company’s cell therapy for Duchenne muscular dystrophy. Kaos Capital has reached out to fellow shareholders, requesting a meeting to nominate two independent board members and establish a committee focused on mergers and acquisitions, as well as strategic alternatives.
The investor contends that Capricor must pivot from being a “single asset bet” and evolve into a more “disciplined biotech platform.” They propose halting non-essential expenditures while pursuing new drug candidates to enhance the Duchenne treatment. Kaos has set a 15-day timeline for discussions with the board and a representative group of shareholders.
Bristol Myers’ AI-Driven Initiatives
Bristol Myers Squibb continues to invest heavily in artificial intelligence for drug discovery. Following a recent partnership with Nvidia to establish a substantial AI data center, the company has now teamed up with Chai Discovery, a promising startup specializing in AI technology for antibody drug development. This collaboration aims to leverage Chai’s AI models to discover new antibody candidates across Bristol Myers’ extensive portfolio and advance the creation of a continuously learning AI-powered discovery system.
Chai Discovery recently secured $400 million in a Series C funding round and has other collaborations with major players in the pharmaceutical industry, including Pfizer, Eli Lilly, and Novartis.
Eli Lilly’s Innovative Vaccine Collaboration
Eli Lilly has announced a partnership with Amplitude Therapeutics to explore the development of “trans-amplifying” vaccines for infectious diseases. This innovative approach involves a type of replicating RNA that may facilitate vaccine delivery into human cells more efficiently than traditional methods. The collaboration promises to produce vaccines that are simpler to manufacture while delivering stronger potency in lower doses.
While specific financial details and targets of the collaboration remain undisclosed, Lilly retains the rights to develop and commercialize any resulting programs. This partnership marks another strategic step for Lilly in the vaccine research arena, following its acquisition of three biotech firms focused on infectious diseases earlier this year.
Kynexis Secures Additional Funding
Kynexis, a developer of therapies for brain disorders, recently announced an extension of its Series A funding, raising an additional 40 million euros. This financing round, led by Novartis’ corporate venture arm, includes participation from Forbion, Ysios Capital, and Sunstone Life Science Ventures. The funds will be allocated to support a mid-stage clinical study of KYN-5356, its lead drug targeting cognitive impairment associated with schizophrenia.
The drug aims to reduce levels of kynurenic acid in the brains of patients, which has been linked to schizophrenia symptoms, by inhibiting an enzyme called KAT-II. Kynexis anticipates reporting topline results from this trial by the end of the year, marking an important milestone in its development timeline.
Network Bio’s Ambitious Data Initiative
A new startup, Network Bio, has successfully secured $50 million in funding to develop a comprehensive “disease-focused dataset.” This dataset is intended to train new AI models aimed at enhancing human health outcomes. Collaborating with biobanks at prestigious academic institutions, including Mass General Brigham and the University of Pennsylvania, Network Bio plans to utilize a vast collection of patient tissue and blood samples to support biomedical research.
The startup has garnered investment from several prominent tech and biotech venture capital firms, including Section 32, Thiel Bio, Founders Fund, and Breyer Capital. Notably, Network Bio has also established a collaboration worth over $30 million with an undisclosed healthcare company.
Takeaways
- Capricor Therapeutics faces pressure from Kaos Capital to reform its governance structure as it approaches an FDA decision on its Duchenne therapy.
- Bristol Myers Squibb is strengthening its AI capabilities through partnerships, seeking to enhance drug discovery processes.
-
Eli Lilly’s collaboration with Amplitude Therapeutics focuses on innovative RNA vaccine technology for infectious diseases.
-
Kynexis has secured additional funding to advance its schizophrenia treatment, with results expected soon.
-
Network Bio aims to build a comprehensive dataset for AI-driven health research, supported by substantial venture capital investment.
The biopharma sector remains dynamic, with companies continually adapting to new challenges and opportunities. Keeping abreast of these developments is essential for stakeholders in this fast-paced industry.
Read more → www.biopharmadive.com